Three stocks hit the circuits today: 63 Moons Technologies, Kitex Garments and Akums Drugs & Pharmaceuticals hit the upper circuit

Domestic equity bourses, NIFTY50 and SENSEX, are trading in the green, advancing by 0.71% and 0.83%, respectively. The Nifty Midcap 100 index and the Nifty Smallcap 100 index are trading in the green, gaining 0.12% and 0.38%, respectively.

On the NSE, 62 stocks hit the upper price band (Upper Circuit) and 18 stocks hit the lower price band (Lower Circuit).

Here is the list of stocks (market cap above ₹1,000 crore) locked in the upper and lower circuits in today’s trading session.

Stocks hitting the upper circuit on Friday (November 29, 2024)

63 Moons Technologies Ltd

63 Moons Technologies is engaged in Computer Programming, Consultancy and related services. The company provides next-generation technology ventures, innovations, platforms, and solutions for creating digital markets and marketplaces that enable price discovery and transaction efficiencies across industry segments. Its focus has always been towards providing technology solutions, building user-friendly financial platforms, and creating digital marketplaces in India and abroad. The company has a market capitalisation of ₹3,000 crore.

Kitex Garments Ltd

The company declared strong financial results for Q2FY25. It reported a 47.79% increase in total income from ₹148.17 crore in Q2FY24 to ₹218.98 crore. PAT has increased by 370.29% from ₹7.81 crore in Q2FY24 to ₹36.73 crore.

Kitex Garments was incorporated in 1992. The company exports cotton and organic cotton garments, especially infant wear to U.S. and European markets. The company has a market capitalisation of ₹4,900 crore.

Sabu Jacob, chairman and managing director of Kitex Garments, in their press release, stated that the turnover, which has reached ₹500 crore, is set to touch ₹1,000 crore in the current fiscal from ₹641 crore in the previous year with this growth momentum. The unrest in Bangladesh has contributed to the financial growth of not only Kitex Garments but the entire garment industry in India. The Telangana Phase I and II will be operational by 2025 and 2026. With this, the total capacity of Kitex will be increased by $0.5 billion.

Akums Drugs & Pharmaceuticals Ltd

Earlier, the company also announced that it has entered into an exclusive Master Sales Agreement with Caregen Co. Ltd, a leading South Korean company in the Nutraceuticals segment. During the term of the agreement, Akums has been granted the exclusive rights to sell certain Caregen products in India.

Established in 2004, Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organisation (CDMO) offering a comprehensive range of pharmaceutical products and services. It has a market capitalisation of ₹9,800 crore.